您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn） 甘李药业股份有限公司 甘李药业股份有限公司 内部控制审计报告 大华内字[2024]0011000204 号 大华会计师事务所(特殊普通合伙) Da Hua Certified Public Accountants (Special General Partnership ) 内部控制审计报告 (截止 2023 年 12 月 31 日) 目 录 页 次 一、 1-2 十代会计师事各折 (特 x 两四环中路 16号院 7号楼 由话:86 (10) 5835 0011 传真:86 ( 内 部 控 制 审 计 报 告 大华内字[2024]0011000204 号 三、内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和发现错报的可能性。 此外,由于情况的变化可能导致内部控制变得不恰当,或对控制政策 和程序遵循的程度降低,根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 甘李药业股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求,我们审计了甘李药业股份有限公司 ...

[Important Content Reminder](index=1&type=section&id=重要内容提示) The board of directors, supervisory board, and senior management guarantee the accuracy and completeness of the quarterly report - The company's board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report content, assuming individual and joint legal responsibility[3](index=3&type=chunk) - The company's head, chief accountant, and head of accounting department guarantee the truthfulness, accuracy, and completeness of the financial information in the quarterly report[3](index=3&type=chunk) - The first quarter financial statements are unaudited[3](index=3&type=chunk) [Key Financial Data](index=2&type=section&id=一、%20主要财务数据) This section presents the company's key financial performance and position indicators for the current reporting period [Key Accounting Data and Financial Indicators](index=2&type=section&id=一、(一)主要会计数据和财务指标) In Q1 2024, operating revenue slightly increased by 0.42% to 560 million Yuan, net profit attributable to shareholders surged by 95.04% to 96 million Yuan, while non-recurring net profit decreased by 42.93% Key Accounting Data and Financial Indicators | Item | Amount for Current Period (Yuan) | Change from Prior Year Period (%) | | :--- | :--- | :--- | | Operating Revenue | 560,334,209.70 | 0.42 | | Net Profit Attributable to Shareholders of Listed Company | 96,004,278.20 | 95.04 | | Net Profit Attributable to Shareholders of Listed Company After Deducting Non-recurring Gains and Losses | 17,169,319.18 | -42.93 | | Net Cash Flow from Operating Activities | 81,288,354.73 | Not Applicable | | Basic Earnings Per Share (Yuan/share) | 0.16 | 77.78 | | Diluted Earnings Per Share (Yuan/share) | 0.16 | 77.78 | | Weighted Average Return on Net Assets (%) | 0.89 | 0.38 | | **Period-End Indicators** | **Amount at End of Current Period (Yuan)** | **Change from Prior Year-End (%)** | | Total Assets | 11,719,954,413.58 | 0.04 | | Owners' Equity Attributable to Shareholders of Listed Company | 10,842,590,528.90 | 0.93 | [Non-recurring Gains and Losses Items and Amounts](index=2&type=section&id=一、(二)非经常性损益项目和金额) Total non-recurring gains and losses for the period were 78.83 million Yuan, primarily from fair value changes of financial assets Non-recurring Gains and Losses Items and Amounts | Non-recurring Gains and Losses Item | Amount for Current Period (Yuan) | | :--- | :--- | | Gains and Losses from Disposal of Non-current Assets | 579,596.73 | | Government Grants Recognized in Current Profit or Loss | 2,069,931.77 | | Gains and Losses from Changes in Fair Value of Financial Assets and Liabilities, and from Disposal of Financial Assets and Liabilities | 87,766,570.01 | | Other Non-operating Income and Expenses Apart from the Above | 1,943,773.17 | | Other Profit and Loss Items Meeting the Definition of Non-recurring Gains and Losses | 470,697.75 | | Less: Income Tax Impact | 13,995,610.41 | | **Total** | **78,834,959.02** | - The company recognizes the amortization of deferred income from asset-related government grants (**2,300,908.72 Yuan**) as recurring gains and losses[6](index=6&type=chunk) [Changes and Reasons for Key Accounting Data and Financial Indicators](index=3&type=section&id=一、(三)主要会计数据、财务指标发生变动的情况、原因) Net profit attributable to shareholders increased significantly by 95.04% due to fair value gains, while non-recurring net profit decreased by 42.93% due to higher R&D expenses Changes and Reasons for Key Accounting Data and Financial Indicators | Item Name | Change Percentage (%) | Primary Reason | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | 95.04 | Primarily due to increased fair value change gains from the company's securities investments during the reporting period | | Net Profit Attributable to Shareholders of Listed Company After Deducting Non-recurring Gains and Losses | -42.93 | Primarily due to increased R&D expenses year-on-year during the reporting period | | Net Cash Flow from Operating Activities | Not Applicable | Primarily due to increased cash received from sales of goods and services and increased tax refunds during the reporting period | | Basic Earnings Per Share | 77.78 | Primarily due to the year-on-year increase in net profit attributable to shareholders of the listed company during the current reporting period | | Diluted Earnings Per Share | 77.78 | Primarily due to the year-on-year increase in net profit attributable to shareholders of the listed company during the current reporting period | [Shareholder Information](index=4&type=section&id=二、%20股东信息) This section details the company's shareholder structure, including the total number of shareholders and the holdings of the top ten [Total Number of Common Shareholders and Top Ten Shareholders' Holdings](index=4&type=section&id=二、(一)普通股股东总数和表决权恢复的优先股股东数量及前十名股东持股情况表) As of the reporting period end, the company had 83,780 common shareholders, with Gan Zhongru as the largest shareholder holding 34.61% of shares, some of which are pledged - The total number of common shareholders at the end of the reporting period was **83,780**[8](index=8&type=chunk) Top Ten Shareholders' Holdings | Shareholder Name | Shareholder Nature | Number of Shares Held | Shareholding Percentage (%) | Number of Restricted Shares Held | Share Status | Number of Pledged, Marked, or Frozen Shares | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Gan Zhongru | Domestic Natural Person | 205,643,757 | 34.61 | 28,508,550 | Pledged | 63,260,000 | | Beijing Xute Hongda Technology Co., Ltd. | Domestic Non-State-Owned Legal Person | 47,494,437 | 7.99 | | None | | | Minghua Innovation Technology Investment (Hong Kong) Co., Ltd. | Overseas Legal Person | 22,154,087 | 3.73 | 15,875,800 | None | | | HKSCC Nominees Limited | Other | 7,253,096 | 1.22 | | None | | | Gan Xiru | Domestic Natural Person | 6,223,276 | 1.05 | | None | | | Vast Wintersweet Limited | Overseas Legal Person | 6,045,405 | 1.02 | 5,777,913 | None | | | Bank of China Ltd. - China Merchants CSI Biomedical Index Fund | Other | 4,626,700 | 0.78 | | None | | | Hillhouse G&L Holdings (HK) Limited | Overseas Legal Person | 4,357,832 | 0.73 | 4,296,032 | None | | | STRONG LINK INTERNATIONAL LIMITED | State-owned Legal Person | 4,256,033 | 0.72 | 4,256,033 | None | | | Agricultural Bank of China Ltd. - Penghua Pharmaceutical Technology Stock Fund | Other | 3,091,600 | 0.52 | | None | | - Gan Zhongru, the controlling shareholder and actual controller, holds **65.02%** equity in Xute Hongda; Gan Xiru is Gan Zhongru's younger sister. No other related party relationships or concerted actions exist among other shareholders[14](index=14&type=chunk) [Top Ten Shareholders of Unrestricted Shares](index=5&type=section&id=前10名无限售流通股股东持股情况) The top ten unrestricted circulating share shareholders largely mirror the overall top ten, with Gan Zhongru holding 177.14 million unrestricted shares Top Ten Shareholders of Unrestricted Shares | Shareholder Name | Number of Unrestricted Circulating Shares Held | Type of Shares | Type and Quantity of Shares | | :--- | :--- | :--- | :--- | | Gan Zhongru | 177,135,207 | RMB Ordinary Shares | 177,135,207 | | Beijing Xute Hongda Technology Co., Ltd. | 47,494,437 | RMB Ordinary Shares | 47,494,437 | | HKSCC Nominees Limited | 7,253,096 | RMB Ordinary Shares | 7,253,096 | | Minghua Innovation Technology Investment (Hong Kong) Co., Ltd. | 6,278,287 | RMB Ordinary Shares | 6,278,287 | | Gan Xiru | 6,223,276 | RMB Ordinary Shares | 6,223,276 | | Bank of China Ltd. - China Merchants CSI Biomedical Index Fund | 4,626,700 | RMB Ordinary Shares | 4,626,700 | | Agricultural Bank of China Ltd. - Penghua Pharmaceutical Technology Stock Fund | 3,091,600 | RMB Ordinary Shares | 3,091,600 | | Zhang Jiazhen | 2,600,000 | RMB Ordinary Shares | 2,600,000 | | China Merchants Bank Co., Ltd. - Southern Alpha Mixed Securities Investment Fund | 2,465,834 | RMB Ordinary Shares | 2,465,834 | | Gan Yiru | 2,215,637 | RMB Ordinary Shares | 2,215,637 | - Mr. Zhang Jiazhen holds **2,600,000 shares** through a credit securities account[14](index=14&type=chunk) [Shareholders' Participation in Securities Lending Business](index=5&type=section&id=前10名股东及前10名无限售流通股股东参与转融通业务情况说明（如有）) Bank of China Ltd. - China Merchants CSI Biomedical Index Fund participated in securities lending, with a decrease in shares lent out from 933,200 to 115,200 Shareholders' Participation in Securities Lending Business | Shareholder Name (Full Name) | Total Shares Held in Ordinary and Credit Accounts at Period Start | Percentage (%) | Total Shares Lent Out Through Securities Lending and Not Yet Returned at Period Start | Percentage (%) | Total Shares Held in Ordinary and Credit Accounts at Period End | Percentage (%) | Total Shares Lent Out Through Securities Lending and Not Yet Returned at Period End | Percentage (%) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Bank of China Ltd. - China Merchants CSI Biomedical Index Fund | 3,788,600 | 0.64 | 933,200 | 0.16 | 4,626,700 | 0.78 | 115,200 | 0.02 | - Changes in the top 10 shareholders and top 10 unrestricted circulating share shareholders occurred due to securities lending/return, but specific details are not provided in the report[16](index=16&type=chunk) [Other Reminders](index=6&type=section&id=三、%20其他提醒事项) No other significant operating information requiring special attention from investors was identified during the reporting period - No other significant operating information requiring special attention from investors was identified during the reporting period[17](index=17&type=chunk) [Quarterly Financial Statements](index=7&type=section&id=四、%20季度财务报表) This section presents the company's unaudited consolidated financial statements for the first quarter of 2024 [Type of Audit Opinion](index=7&type=section&id=四、(一)审计意见类型) The financial statements for the current quarter are unaudited - The financial statements for the current quarter are unaudited[18](index=18&type=chunk) [Financial Statements](index=7&type=section&id=四、(二)财务报表) This section includes the consolidated balance sheet, income statement, and cash flow statement for Q1 2024, detailing the company's financial position, performance, and cash movements [Consolidated Balance Sheet](index=7&type=section&id=合并资产负债表) As of March 31, 2024, total assets were 11.72 billion Yuan, a slight increase of 0.04% from year-end, with total liabilities at 877 million Yuan and total owners' equity at 10.84 billion Yuan Consolidated Balance Sheet | Item | March 31, 2024 (Yuan) | December 31, 2023 (Yuan) | Change (Yuan) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | 2,552,990,893.78 | 2,442,708,603.20 | 110,282,290.58 | 4.51 | | Financial Assets Held for Trading | 2,346,980,905.99 | 2,410,429,796.82 | -63,448,890.83 | -2.63 | | Accounts Receivable | 269,599,231.21 | 383,735,270.90 | -114,136,039.69 | -29.75 | | Inventories | 932,042,171.36 | 860,506,306.14 | 71,535,865.22 | 8.31 | | Total Current Assets | 6,215,027,747.41 | 6,175,749,710.54 | 39,278,036.87 | 0.64 | | Total Non-current Assets | 5,504,926,666.17 | 5,539,273,761.26 | -34,347,095.09 | -0.62 | | **Total Assets** | **11,719,954,413.58** | **11,715,023,471.80** | **4,930,941.78** | **0.04** | | Total Current Liabilities | 682,351,020.81 | 773,449,046.88 | -91,098,026.07 | -11.78 | | Total Non-current Liabilities | 195,012,503.62 | 199,067,997.28 | -4,055,493.66 | -2.04 | | **Total Liabilities** | **877,363,524.43** | **972,517,044.16** | **-95,153,519.73** | **-9.78** | | Total Owners' Equity Attributable to Parent Company | 10,842,590,528.90 | 10,742,506,022.92 | 100,084,505.98 | 0.93 | | **Total Owners' Equity** | **10,842,590,889.15** | **10,742,506,427.64** | **100,084,461.51** | **0.93** | [Consolidated Income Statement](index=9&type=section&id=合并利润表) In Q1 2024, total operating revenue was 560 million Yuan, a 0.42% increase, with net profit reaching 96 million Yuan, up 95.04%, primarily driven by significant fair value gains Consolidated Income Statement | Item | Q1 2024 (Yuan) | Q1 2023 (Yuan) | Change (Yuan) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Total Operating Revenue | 560,334,209.70 | 557,999,537.96 | 2,334,671.74 | 0.42 | | Total Operating Costs | 541,954,966.18 | 528,077,591.01 | 13,877,375.17 | 2.63 | | Selling Expenses | 227,086,625.00 | 224,729,850.74 | 2,356,774.26 | 1.05 | | Administrative Expenses | 43,299,233.12 | 46,800,804.48 | -3,501,571.36 | -7.48 | | Research and Development Expenses | 133,120,155.74 | 119,936,250.47 | 13,183,905.27 | 11.00 | | Gains from Changes in Fair Value | 85,501,251.91 | 17,706,102.62 | 67,795,149.29 | 382.90 | | Operating Profit | 113,115,835.01 | 59,826,046.76 | 53,289,788.25 | 89.08 | | Total Profit | 113,560,343.98 | 57,690,582.56 | 55,869,761.42 | 96.84 | | Income Tax Expense | 17,556,110.25 | 8,467,364.65 | 9,088,745.60 | 107.33 | | **Net Profit** | **96,004,233.73** | **49,223,217.91** | **46,781,015.82** | **95.04** | | Net Profit Attributable to Parent Company Shareholders | 96,004,278.20 | 49,223,261.29 | 46,781,016.91 | 95.04 | | Basic Earnings Per Share (Yuan/share) | 0.16 | 0.09 | 0.07 | 77.78 | | Diluted Earnings Per Share (Yuan/share) | 0.16 | 0.09 | 0.07 | 77.78 | [Consolidated Cash Flow Statement](index=11&type=section&id=合并现金流量表) Net cash flow from operating activities significantly improved to 81.29 million Yuan in Q1 2024, up from a negative 16.26 million Yuan in the prior year, mainly due to increased sales and tax refunds Consolidated Cash Flow Statement | Item | Q1 2024 (Yuan) | Q1 2023 (Yuan) | Change (Yuan) | | :--- | :--- | :--- | :--- | | Cash Received from Sales of Goods and Rendering of Services | 648,170,407.38 | 521,288,359.88 | 126,882,047.50 | | Tax Refunds Received | 35,184,163.91 | 19,057,286.19 | 16,126,877.72 | | Subtotal of Cash Inflows from Operating Activities | 688,698,883.71 | 546,877,814.78 | 141,821,068.93 | | Subtotal of Cash Outflows from Operating Activities | 607,410,528.98 | 563,137,935.55 | 44,272,593.43 | | **Net Cash Flow from Operating Activities** | **81,288,354.73** | **-16,260,120.77** | **97,548,475.50** | | Subtotal of Cash Inflows from Investing Activities | 2,330,957,463.52 | 1,538,689,953.92 | 792,267,509.60 | | Subtotal of Cash Outflows from Investing Activities | 2,359,857,245.63 | 1,584,096,806.70 | 775,760,438.93 | | **Net Cash Flow from Investing Activities** | **-28,899,782.11** | **-45,406,852.78** | **16,507,070.67** | | Net Cash Flow from Financing Activities | -951,940.65 | -918,525.58 | -33,415.07 | | Net Increase in Cash and Cash Equivalents | 51,481,078.54 | -64,171,449.11 | 115,652,527.65 | [Adjustments for First-Time Adoption of New Accounting Standards](index=12&type=section&id=四、(三)2024%20年起首次执行新会计准则或准则解释等涉及调整首次执行当年年初的财务报表) The company did not make any adjustments to its opening financial statements for the current year due to the first-time adoption of new accounting standards or interpretations - The company did not make any adjustments to its opening financial statements for the current year due to the first-time adoption of new accounting standards or interpretations during the reporting period[24](index=24&type=chunk)

中信证券股份有限公司 关于甘李药业股份有限公司 2023 年度募集资金存放与使用情况的专项核查报告 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）作为甘李 药业股份有限公司（以下简称"甘李药业"或"公司"）首次公开发行股票并在 上海证券交易所主板上市的保荐机构，根据《中华人民共和国证券法》、《证券 发行上市保荐业务管理办法》、《上海证券交易所股票上市规则》等相关规定， 对公司 2023 年度募集资金存放与使用情况进行了专项核查，具体情况如下： 一、募集资金基本情况 （一）2020 年首次公开发行股票募集资金基本情况 经中国证券监督管理委员会以"证监许可[2020]1075 号"文《关于核准甘李 药业股份有限公司首次公开发行股票的批复》核准，公司向社会公开发行人民币 普通股 40,200,000 股（A 股），每股面值人民币 1 元，发行价格为人民币 63.32 元/股，募集资金总额为人民币 2,545,464,000.00 元。扣减发行上市费用人民币 104,329,536.23 元（由于本公司对外销售自产的胰岛素产品按 3%的简易征收率 缴纳增值税，不予抵扣进项税，上述发行费用包含增值税金）后， ...

公司代码：603087 公司简称：甘李药业 甘李药业股份有限公司 2023 年度内部控制评价报告 甘李药业股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内 部控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专 项监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了 评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露 内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责 组织领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内 容不存在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别 及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整， 提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标 提供合理保证。此外，由于情况的变化可能导致内 ...

证券代码：603087 证券简称：甘李药业 公告编号：2024-026 甘李药业股份有限公司 关于公司参加全国药品集中采购（胰岛素专项接续） 拟中标的公告 公司此次保持中选类别不变，所有参加组别均有拟中选 A 类品种。因上轮 报价方案经由市场检验，具有科学性、有效性，胰岛素接续采购各产品中选类别 符合公司经营发展规划，保障公司健康持续发展。同时，各产品拟中选类别符合 国家政策导向与广大糖尿病患者的用药需求。 根据联合采购办公室发布的胰岛素接续采购拟中选结果公示文件，公司参与 申报的精蛋白人胰岛素混合注射液（30R）、赖脯胰岛素注射液、门冬胰岛素注 射液、甘精胰岛素注射液、精蛋白锌重组赖脯胰岛素混合注射液（25R）及门冬 胰岛素 30 注射液等品种在胰岛素接续采购中均获得拟中选资格，所有参加组别 均有拟中选 A 类品种。现将相关情况公告如下： 一、拟中标产品的基本情况 | 拟中 | | | 序 | 采购组名 | | | 拟中选 | | 首年采购 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 品种名称 | | | ...

证券研究报告 | 首次覆盖报告 2024年04月12日 甘李药业（603087.SH） 国产三代胰岛素领先者，主业稳健，出海打造第二增长曲线 核心投资逻辑：我们认为，胰岛素集采续约后竞争格局将迎来3年左右的 买入（首次） 稳定期，且本次规则整体温和，公司胰岛素主业风险出尽，同时公司积极 股票信息 推进生物类似物出海，海外放量可期，第二增长曲线雏形已现。此外，公 司于2024年推出第二轮股权激励计划，目标较高，彰显发展信心。 行业 生物制品 4月09日收盘价（元） 44.26 国产三代胰岛素领先者，集采续标落地利空出尽。2021 年国家专项胰岛 总市值（百万元） 25,875.74 素集采中，公司全线 6 款胰岛素产品高顺位中标，助力销量迅速增长。 总股本（百万股） 594.16 2023H1，公司实现扭亏为盈，营收同比+47.31%，国内制剂销量同比 其中自由流通股（%） 89.38 +104.75%，其中速效和预混胰岛素销量同比+167.97%，以价换量效果 显著。2024 年3 月，胰岛素集采续约文件发布，整体规则温和，公司重 30 日日均成交量（百万 9.92 点品种（如甘精）有望提价，且本次标期将至2 ...

证券代码：603087 证券简称：甘李药业 公告编号：2024-025 甘李药业股份有限公司 关于 GZR18 片中国Ⅰ期临床试验完成首例受试者给 药的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 三、风险提示 甘李药业股份有限公司（以下简称"甘李药业"、"公司"）全资子公司甘 李药业山东有限公司自主研发的 GZR18 片正在中国开展Ⅰ期临床试验，于今日 完成首例受试者给药。现将相关情况公告如下： 一、GZR18 片的基本情况 GZR18 片是 GLP-1 类似物 GZR18 的口服剂型。GZR18 是甘李药业在研的 一种长效 GLP-1 受体激动剂（GLP-1 RA），具有体内代谢半衰期长的特点，作 用机制是能结合并激活胰高血糖素样肽-1 受体（GLP-1R）促进胰岛β细胞的胰 岛素释放，抑制胰岛α细胞释放胰高血糖素，同时延缓胃排空并抑制食欲而综合 调控降低血糖，改善肥胖。 二、GZR18 片的研发情况及进展 该产品于 2023 年 11 月获得国家药品监督管理局下发的《药品临床试验批准 通知书》（通知书编号：202 ...

证券代码：603087 证券简称：甘李药业 公告编号：2024-023 具体内容详见公司于同日在上海证券交易所网站披露的《甘李药业股份有限 公司关于使用闲置自有资金进行现金管理的公告》（公告编号：2024-024）。 表决结果：3 票同意、0 票反对、0 票弃权。 特此公告。 甘李药业股份有限公司 第四届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 甘李药业股份有限公司（"公司"）第四届监事会第十六次会议于 2024 年 3 月 23 日以电子邮件方式发出会议通知和会议材料，2024 年 3 月 28 日在公司 五层会议室以现场会议的形式召开。本次会议由监事会主席张涛先生主持。应出 席监事 3 名，实际出席监事 3 名。本次会议的召开符合《公司法》和《公司章程》 的有关规定，会议决议合法有效。 二、监事会会议审议情况 经与会监事审议表决，一致通过如下议案： （一）审议通过了《关于公司使用闲置自有资金进行现金管理的议案》 同意公司在保障资金安全及确保不影响公司正常经营的情况下 ...

甘李药业股份有限公司 关于使用闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603087 证券简称：甘李药业 公告编号：2024-024 投资金额：不超过人民币 40 亿元。 投资期限：自甘李药业股份有限公司（以下简称"公司"）第四届董事会 第十七次会议审计通过之日起 12 个月。 投资种类：安全性高、流动性好，风险较低且投资回报相对较好的理财 产品（包括结构性存款、收益凭证、信托产品、资产管理计划、债券基金、货币 型基金等）。 履行的审议程序：2024 年 3 月 28 日，公司召开第四届董事会第十七次 会议及第四届监事会第十六次会议审议通过了《关于公司使用闲置自有资金进行 现金管理的议案》。 特别风险提示：尽管公司购买安全性高、流动性好，风险较低且投资回 报相对较好的理财产品，但金融市场受宏观经济的影响较大，不排除该项投资受 到市场剧烈波动的影响。公司将根据经济形势以及金融市场的变化适时适量介入， 因此短期投资的实际收益不可预期。 公司于 2024 年 3 月 2 ...

大华作为公司 2023 年度审计机构，原指派冯雪女士担任项目质量控制复核 人，因冯雪女士工作调整，现指派周鑫先生作为项目质量控制复核人，继续完成 公司 2023 年度财务报表和内部控制的审计工作。 二、本次变更后的项目质量控制复核人信息 1、项目质量控制复核人：周鑫先生，2007 年 11 月成为中国注册会计师， 2019 年 1 月开始从事上市公司和挂牌公司审计，2013 年 8 月开始在大华执业， 2022 年 1 月开始从事复核工作；近三年签署或复核上市公司和挂牌公司审计报 告数量超过 4 家次。 证券代码：603087 证券简称：甘李药业 公告编号：2024-022 甘李药业股份有限公司 关于审计机构变更项目质量控制复核人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 甘李药业股份有限公司（以下简称"公司"）于 2023 年 3 月 29 日召开了第 四届董事会第十次会议，会议审议通过了《关于续聘公司 2023 年度会计师事务 所及决定其报酬的议案》，同意续聘大华会计师事务所（特殊普通合伙）（以下 简称"大华" ...